##semicolon##
ўпканинг сурункали обструктив касаллиги, юрак ишемик касаллиги, коморбитлик.##submission.citations##
Бакина Анастасия Алексеевна, Павленко Валентина Ивановна Хроническая болезнь почек как проявление коморбидности у больных хронической обструктивной болезнью легких Бюл. физ. и пат. дых.. 2018. №69. (дата обращения: 10.06.2023).
Таютина, Т. В., Бортников, А. Ю., Лысенко, А. В., Казарян, Т. М., & Экнадиосова, Д. В. (2024). Структура летальности и сопутствующей патологии у больных с хронической обструктивной болезнью легких: параллели с патоморфологическими легочными изменениями. Медицина: теория и практика, 9(1), 4-17. https://doi.org/10. 56871/MTP.2024.61.67.001
Чаулин А.М., Карслян Л.С., Базюк Е.В., Нурбалтаева Д.А., Дупляков Д.В. Клинико-диагностическая ценность кардиомаркеров в биологических жидкостях человека. Кардиология. 20 19;59(11):66–75. 1→48.
Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should) Proc Am Thorac Soc. 2007.Vol. 4. Р. 522–525.Х→21→.
Agustí A., Noell G., Brugada J., Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir. Med. 2017;5(12):935–945. 1→59.
Balbirsingh V, Mohammed AS, Turner AM, et alCardiovascular disease in chronic obstructive pulmonary disease: a narrative reviewThorax 2022; 77:939-94.
Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, Chaudhuri N, Schelbert EB, Potluri R, Miller CA. Association of Cardiovascular Disease With Respiratory Disease. J Am Coll Cardiol. 2019 May 7;73(17):2166-2177. doi: 10.1016/j.jacc.2018.1 1.063.
Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072.
Cohen A.J., Brauer M., Burnett R., Anderson H.R., Frostad J., Estep K. et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389(10082):1907–1918.
Gembillo G, Calimeri S, Tranchida V, Silipigni S, Vella D, Ferrara D, Spinella C, Santoro D, Visconti L. Lung Dysfunction and Chronic Kidney Disease: A Complex Network of Multiple Interactions. J Pers Med. 2023 Feb 3;13(2):286. doi: 10.3390/jpm 13020286; McMahon, T.J., Prybylowski, A.C. (2018).
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Update 2016. URL:www.goldcopd.com.
Hassan A, Jabbar N. C-reactive Protein as a Predictor of Severity in Chronic Obstructive Pulmonary Disease: An Experience From a Tertiary Care Hospital. Cureus. 2022 Aug 21;14(8):e28229. doi: 10.7759/cureus.28229.
Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular Disease. Int J Mol Sci. 2022 Oct 26;23(21):12906. doi: 10.3390/ijms232112906.
Kahnert K, Jörres RA, Behr J, Welte T. The Diagnosis and Treatment of COPD and Its Comorbidities. Dtsch Arztebl Int. 2023 Jun 23;120(25):434-444. doi: 10.3238/arztebl.m2023.027.
Kang HR, Kim SJ, Nam JG, Park YS, Lee CH. Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality. Int J Chron Obstruct Pulmon Dis. 2024 Jun 7;19:1261-1272. doi: 10.2147/ COPD.S458356.
Katajisto M., Kupiainen H., Rantanen P., Lindqvist A., Kilpelainen M, Tikkanen H. et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int. J. Chron. Obstruct. Pulmon. Dis. 2012;7:743–755. 1→31.
Kida Y., Goligorsky M.S. Sirtuins, Cell Senescence, and Vascular Aging. Can. J. Cardiol. 2016; 32(5):634–641. 1→42.
King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015 Dec;4(1):68. doi: 10.1186/s40169-015-0068-z. Epu b 2015 Jul 29. PMID: 26220864; PMCID: PMC4518 022.
Liu X, Chen Z, Li S, Xu S. Association of Chronic Obstructive Pulmonary Disease With Arrhythmia Risks: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021 Sep 30;8:732349. doi: 10.3389/fcvm.2021.732349.
Lozano R, Naghavi M, Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. 2012. Vol.380, №9859. Р.2095–2128.
Marchetti N., Ciccolella D.E., Jacobs M.R., Crookshank A., Gaughan J.P., Kashem M.A. et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011;8(2):60–65. 1→25.
Rodrigues SdO, Cunha CMCd, Soares GMV, Silva PL, Silva AR, Gonçalves-de-Albuquerque CF. Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease. Pharmaceuticals. 2021; 14(10):979. https: //doi.org/10.3390/ph14100979.
Roversi S., Fabbri L.M., Sin D.D., Hawkins N.M., Agusti A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am. J. Respir. Crit. Care Med. 2016;194 (11):1319–1336.1-6.
Seidel D., Cheung A., Suh E.S., Raste Y., Atakhorrami M., Spruit M.A. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int. J. Tuberc. Lung Dis. 2012;16(8):1015–1019.1→2.
Turner A., Mulla A., Booth A., Aldridge S., Stevens S., Battye F. et al. An evidence synthesis of the international knowledge base for new care models to inform and mobilise knowledge for multispecialty community providers (MCPs). Syst. Rev. 2016;5(1):167.1-3,
Van Remoortel H., Hornikx M., Langer D., Burtin C., Everaerts S., Verhamme P. et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2014;189(1):30–38. 1→30.
Wang JJ. Risk of Coronary Heart Disease in People with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2021;16:2939-2944 https://doi.org/10.2147/COP D.S331505.